is a new online resource designed to meet the evolving needs of physicians. It brings together elements from Advanstar's trusted healthcare journals along with powerful tools, resources, decision support and advisory functions.Mark LoweryContent EditorAdvanstar Communications Inc...
Expand Your World with Science Learn and share the most exciting discoveries, innovations and ideas shaping our world today.SubscribeSign up for our newslettersSee the latest storiesRead the latest issueGive a Gift Subscription Follow Us:Return & Refund Policy About Press Room FAQs Contact Us Intern...
Jean Readdy, a retired teacher living in Sinking Spring, Pennsylvania, is among the one in eight Americans who have tried a GLP-1 drug for weight loss or diabetes, more commonly known by brand names like Ozempic and Wegovy. Readdy, who has struggled with her weight for most of her life,...
Weight-loss drugs are poised to revolutionise healthcare by slowing down the ageing process and by allowing people to live for longer and in better health. That is the dramatic message from leading …
Evaluate weight loss at 12 weeks on the maintenance dose; if 1% or more of body weight has not been lost, it is unlikely the patient will achieve and sustain clinically meaningful weight loss with continued treatment and this drug should be discontinued. ...
Amphetamine-derivative, stimulant type weight loss drugs may be associated with constipation, dry mouth, restlessness, withdrawal effects, or insomnia (difficulty falling asleep), drug abuse and addiction. Many of the weight loss drugs known as sympathomimetic amines can stimulate the heart and lead ...
A study published in October founda higher risk of bowel obstructionand stomach paralysis for patients taking certain GLP-1 drugs for weight loss when compared with another weight loss drug combination, though those complications were relatively rare. ...
There is a divideamong some physiciansabout if and when children should use weight-loss drugs, which have surged in popularity among adults. In a recent study published in the New England Journal of Medicine, researchers found that Novo Nordisk's drug liraglutide, sold under the...
and she doesn't advertise that she's taking a weight-loss drug, though she'll be honest if people ask. Her doctor has been reluctant to prescribe her a GLP-1 medication, meaning she's still paying out of pocket. She thinks the reluctance was part of what landed her in a bad spot ...
the first time the FDA voted to approve a weight-loss drug in more than a decade. Originally known as Qnexa, the FDA required Vivus, the manufacturer of the drug, to change its name in order to prevent its confusion with other drugs with similar-sounding names. Data presented by the comp...